uniQure (NASDAQ:QURE) Stock Rating Cut to “Equal Weight” at Barclays

Barclays lowered shares of uniQure (NASDAQ:QURE) from an overweight rating to an equal weight rating in a research report released on Monday, Marketbeat reports. The firm currently has $28.00 price target on the biotechnology company’s stock, down from their prior price target of $60.00.

QURE has been the topic of several other reports. Wells Fargo & Company reissued an “overweight” rating and issued a $75.00 price target on shares of uniQure in a research note on Tuesday, September 29th. Leerink Partners raised their price objective on shares of uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Royal Bank Of Canada lowered their price objective on shares of uniQure from $65.00 to $48.00 and set an “outperform” rating for the company in a research note on Friday. Weiss Ratings upgraded shares of uniQure from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 21st. Finally, The Goldman Sachs Group cut their target price on shares of uniQure from $46.00 to $31.00 and set a “neutral” rating on the stock in a research note on Wednesday, September 30th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, uniQure currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.73.

uniQure Stock Performance

Shares of uniQure stock opened at $22.80 on Monday. The company has a current ratio of 10.01, a quick ratio of 10.01 and a debt-to-equity ratio of 0.15. The business has a 50-day moving average price of $42.99 and a two-hundred day moving average price of $33.50. uniQure has a 1-year low of $8.73 and a 1-year high of $71.50. The company has a market cap of $1.58 billion, a P/E ratio of -5.69 and a beta of 1.06.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.40). uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%.The business had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.45 million. During the same period last year, the business posted ($0.69) earnings per share. As a group, analysts anticipate that uniQure will post -3.82 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in QURE. IFP Advisors Inc increased its position in shares of uniQure by 39.8% during the second quarter. IFP Advisors Inc now owns 2,780 shares of the biotechnology company’s stock worth $128,000 after acquiring an additional 791 shares in the last quarter. Mraz Amerine & Associates Inc. bought a new position in uniQure in the 2nd quarter valued at about $390,000. Arizona State Retirement System boosted its stake in uniQure by 17.7% during the 2nd quarter. Arizona State Retirement System now owns 12,940 shares of the biotechnology company’s stock valued at $596,000 after purchasing an additional 1,942 shares during the last quarter. Syon Capital LLC acquired a new position in uniQure during the 2nd quarter valued at about $279,000. Finally, Seven Fleet Capital Management LP bought a new stake in uniQure during the 2nd quarter worth approximately $15,254. 78.83% of the stock is owned by institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on developing gene therapies intended to treat serious and potentially life-threatening diseases. The company uses adeno-associated virus (AAV) delivery technology to introduce genetic material into patients’ cells, with the goal of addressing the underlying causes of disease through a single administration.

uniQure’s lead commercial product, Hemgenix (etranacogene dezaparvovec), is a gene therapy for adults with hemophilia B who use factor IX replacement therapy.